JP2007520566A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520566A5
JP2007520566A5 JP2006552302A JP2006552302A JP2007520566A5 JP 2007520566 A5 JP2007520566 A5 JP 2007520566A5 JP 2006552302 A JP2006552302 A JP 2006552302A JP 2006552302 A JP2006552302 A JP 2006552302A JP 2007520566 A5 JP2007520566 A5 JP 2007520566A5
Authority
JP
Japan
Prior art keywords
autoantigen
antibody
pharmaceutical composition
antigen
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006552302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/003712 external-priority patent/WO2005076965A2/en
Publication of JP2007520566A publication Critical patent/JP2007520566A/ja
Publication of JP2007520566A5 publication Critical patent/JP2007520566A5/ja
Pending legal-status Critical Current

Links

JP2006552302A 2004-02-04 2005-02-04 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法 Pending JP2007520566A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195904P 2004-02-04 2004-02-04
PCT/US2005/003712 WO2005076965A2 (en) 2004-02-04 2005-02-04 Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity

Publications (2)

Publication Number Publication Date
JP2007520566A JP2007520566A (ja) 2007-07-26
JP2007520566A5 true JP2007520566A5 (https=) 2008-03-27

Family

ID=34860238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552302A Pending JP2007520566A (ja) 2004-02-04 2005-02-04 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法

Country Status (7)

Country Link
US (1) US20070190045A1 (https=)
EP (1) EP1725254A4 (https=)
JP (1) JP2007520566A (https=)
AU (1) AU2005213449A1 (https=)
CA (1) CA2554978A1 (https=)
IL (1) IL177193A0 (https=)
WO (1) WO2005076965A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20050004001A1 (en) * 2002-10-02 2005-01-06 Robert Harris Formulation of antigen
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
BRPI0607117A2 (pt) * 2005-02-04 2009-08-11 Dow Agrosciences Llc tratamento com anticélulas t e auto-antìgeno de doença auto-imune
AU2006267090B2 (en) * 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
US20100061984A1 (en) * 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
SG10201504662WA (en) * 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
US20100015142A1 (en) * 2006-12-21 2010-01-21 Macrogenics Inc. Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
CN103933563B (zh) 2007-01-25 2016-09-28 英特瑞克斯顿阿克图比奥帝克斯有限公司 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病
US20090092637A1 (en) * 2007-04-24 2009-04-09 Diamyd Therapeutics Ab Medicaments and methods to treat autoimmune disease and cancer
JP2013508392A (ja) * 2009-10-20 2013-03-07 グラクソ グループ リミテッド 自己免疫疾患における抗ｃｄ３抗体の投薬
WO2011091138A1 (en) * 2010-01-20 2011-07-28 Bayhill Therapeutics, Inc. Combination therapy to treat autoimmune diseases
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
CN103372214B (zh) * 2012-04-13 2017-09-29 北京艾棣维欣生物技术有限公司 治疗和/或预防ⅰ型糖尿病的药物组合物及其应用
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20170196949A1 (en) * 2014-06-04 2017-07-13 Diamyd Medical Ab Novel combinations for antigen based therapy
US12605432B2 (en) 2014-06-04 2026-04-21 Diamyd Medical Ab Combinations for antigen based therapy
GB201510056D0 (en) * 2015-06-10 2015-07-22 King S College London Multi-peptide composition
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019028503A1 (en) * 2017-08-07 2019-02-14 St Vincent's Institute Of Medical Research THERAPY OF DIABETES TYPE 1
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
PL4069278T3 (pl) 2019-12-06 2025-10-06 Dr. Mary Morris & Associates, Llc Sposoby i kompozycje do zapobiegania cukrzycy typu 1
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CN119095873A (zh) 2022-03-14 2024-12-06 拉姆卡普生物伽马股份公司 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406696B1 (en) * 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6420140B1 (en) * 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
US7378089B2 (en) * 2001-10-02 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
US20040037826A1 (en) * 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound

Similar Documents

Publication Publication Date Title
JP2007520566A5 (https=)
JP2005518433A5 (https=)
JP2007527914A5 (https=)
IL191117A (en) Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor
EA201100958A1 (ru) Фармацевтическая пероральная дозированная лекарственная форма на основе ингибиторов dpp iv
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
EA201390450A1 (ru) Полипептиды с увеличенной продолжительностью действия
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
IL197831A (en) Human antibodies that bind 4cxcr, preparations containing them and their uses
JP2009521520A5 (https=)
JP2007522094A5 (https=)
IL199216A (en) Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses
JP2012509886A5 (https=)
NO20083785L (no) Funksjonelle antistoffer
AR074777A1 (es) Proteinas de union a antigeno
IL178838A (en) Antibodies that specifically bind to human p-psgl-1 and p-selectin, pharmacological preparations containing such antibody, and momentary acids and their encoded vectors
IL209499A (en) Human monoclonal antibody against influenza a virus, pharmaceutical compositions comprising the same and use thereof as medicaments
JP2009505678A5 (https=)
JP2007517055A5 (https=)
WO2009114040A3 (en) Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
WO2018116267A3 (en) Methods of treatment with anti-factor xi/xia antibodies
JP2011528897A5 (https=)
IL179240A (en) Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
MA37645B1 (fr) Formulations stabilisées contenant des anticorps anti-dll4